The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

Euronews Health looks at some of this year’s top medical advances and the key areas of health that were the most solicited ...

It is a cousin of semaglutide, the main ingredient in the wildly popular medications Ozempic and Wegovy (SN ... can help some people with heart failure. The trial included people whose hearts ...

The quest for effective weight loss solutions has never been more urgent, with millions of people worldwide struggling to ...

Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-los ...

The European Medicines Agency’s backing comes after a trial earlier this year showed that Ozempic slows the progression of chronic kidney disease and cuts the risk of kidney failure, heart ...

Diabetes and heart health are closely connected. People with diabetes have a higher risk of heart failure, a condition where ...

Novo Nordisk is running three late-stage trials of semaglutide, the active ingredient in its Ozempic and Wegovy ... by nearly two-thirds and cut heart failure outcomes in a separate trial.

The primary use for Ozempic is to help patients with type 2 diabetes lower their blood sugar if it goes too high. Secondly, it has been found to prevent heart disease, heart failure, stroke and ...

Novo Nordisk is running late-stage trials of semaglutide, the active ingredient in its Ozempic and Wegovy drugs ... by nearly two-thirds and cut heart failure outcomes in a separate trial.